EuResist Network is accepted as member of the UN Global Compact!
EuResist Network joins the UN Global Compact, the world's largest corporate initiative based on CEO commitments to implement universal sustainability principles and to take steps to support UN goals. See the Italian participants.
PhD fellowship on HIV molecular epidemiology
A PhD fellowship on HIV molecular epidemiology has been funded by the EuResist Network at the PhD programme in Data Science of Sapienza University of Rome. The PhD in Data Science of Sapienza is a multidisciplinary doctoral program coordinated by the Department of Computer, Control and Management Engineering "Antonio Ruberti".
The student supported by the fellowship, who has already been selected, will focus on epidemiology of subtype A in the EuResist Integrated DataBase.
The CARE project publishes its first results
In only ten months of activity the CARE partners created a solid ethics permissions, data and samples sharing infrastructure for a wide network of collaboration against HIV, TB and HCV. Already three papers have been published on HIV-1 resistance and epidemiology and the poster "HIV-1 A6 Subtype: its challenging identification and Southern Russian molecular epidemiology" (S. Sierra et al.) will be presented at EACS 2019!
The CARE project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.
Data from over 103, 000 HIV patients in EIDB
The EIDB, expanded to collect clinical and resistance information, contains now data from over 103, 000 HIV patients, The DB is always available for HIV research studies, subject to approval by the Scientific Board. If you are interested to submit a study please contact us.
Two posters from the EuResist Mentor School to be presented at EACS 2019
The two studies: “A retrospective analysis of the EuResist data set assessing dual therapy success in a real-life context” and “A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone” have been realized by the participants of the EMS 2018 under guidance of the trainer M. Bohm and of EuResist Network mentors.
The project has been supported by Janssen Parmaceutical and Gilead Sciences.
INTEGRATE at EACS 2019
The INTEGRATE project results will be presented at. EACS 2019, to be held in Basel on November 6-9 2019, with an oral talk entitled "Prevalence of InSTI resistance and effectiveness of InSTI based regimens in HIV infected patients: results from a European cohort" (B. Brossetti et al.). The presentation will take place on Thursday, November 7th 2019 during the session "Basic and translational HIV biology" (14:00-16:00).
The project has been supported by an unrestricted grant from Gilead Sciences.
EuResist at the PROHIV 2019 international conference on HIV and AIDS, Moscow 23-24 September 2019
EuResist will be present with a talk entitled "The EuResist Integrated DataBase: how to exploit real life data for the study of HIV drug resistance" at the PROHIV 2019 international conference on HIV and AIDS to be held in Moscow on September 23-24 2019.
Two abstracts from the EMS at the 17th European Meeting on HIV & Hepatitis May 2019
Two studies realised by the students of the EuResist Mentor School under the guidance of the tutors will be presented as posters at the European HIV & Hep Meeting in Rome 22-24 May 2019.
EuResist at the AREVIR meeting 3-4 May 2019
EuResist recent results will be presented in the EuResist session within the annual AREVIR meeting in Cologne 3-4 May 2019.
The CARE project breakes the news
Read it on Il Sole 24 ore sanità!
CARE project kick-off meeting 23-24 January
The CARE project kick-off meeting will be in Rome on 23-24 January
Abstract on INTEGRATE dataset accepted at CROI 2019
The study on "GSS of NRTI-backbone predicts time to virological failure of InSTIs-based regimens" realised on INTEGRATE data has been accepted for poster presentation at CROI 2019
in Seattle 4-7 March 2019.
CARE project accepted for funding by the EC under the topic H2020-SC1-BHC-21-2018 of the H2020 programme
CARE is a COMMON ACTION AGAINST HIV/TB/HCV ACROSS THE REGIONS OF EUROPE, coordinated by EuResist Network with scientific coordination of CHIP/RegionH
The on-site part of the novel training initiative by EuResist Network has been held in Cologne involving 30 students, on 3 May 2018.
EuResist at the AREVIR meeting 4-5 May 2018
EuResist recent results will be presented in the EuResist session within the annual AREVIR meeting in Cologne 4, 5 May 2018.
The study "Factorial HMM with Collapsed Gibbs Sampling for optimizing long-term HIV Therapy", realised on the EIDB has been accepted for presentation at the conference.
The EuResist Mentor School (EMS) is a training programme addressed to young virologists and clinicians to learn the basics of database querying (query scientific analysis, SQL language and statistics). Consult the programme and find the instructions on how to apply to participate here.
The study on II line resistance carried out by EuResist and its African partners has been presented as a poster at the XXVI international workshop on HIV drug resistance and treatment strategies, held on 6-8 November in Johannesburg.
EuResist at the EACS 2017 with 5 posters
25-27 October 2017
18 August 2017
Bioinformatics has accepted the manuscript: "PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context, P. Liebin et al. The PhyloGeoTool has been realised in the frame of the EucoHIV project.
The study on II line resistance carried out by EuResist and its African partners has been accepted at the XXVI international workshop on HIV drug resistance and treatment strategies that will be held on 6-8 November in Johannesburg.
Yaounde, Cameroon - 6-8 July 2017
The collaboration with CIRCB, University of Tor Vergata and I-PRO has started in the frame of the National workshop on "HIV test and treat strategy in Cameroon". The project is finalised to the realisation of a DHIS2 HIV resistance DB for Cameroon.
12-14 June 2017
Three abstracts from the AMS experience have been accepted at ICAR for oral presentations. This brings to 6 the number of abstracts accepted at national/international conferences coming from the work performed at AMS2016.
The EIDB has been updated. It now contains data of more than 81.000 patients. The EIDB is open for scientific studies under approval by the Scientific Board.
7 - 9 June 2017
5 - 6 May 2017
Thanks to the funding by Gilead Sciences Europe, the INTEGRATE project can take off. The project, devoted to the collection and analysis of clinical and virological data related to the use of INSTIs, will start with collection of data from the EuResist partners and will then widen the data collection.
Oslo, Norway - Feb 2017 - DHIS2 community, coordinated by the Department of Informatics at the University of Oslo selected as the User Story of the month the KRG-DHIS Pilot project, funded by the Italian Ministry of Foreign Affairs and International Cooperation, led by the University of Rome Tor Vergata in cooperation with the Ministry of Health of the Kurdistan Regional Government, and realized by I-PRO and EuResist Network.
6 Jan 2017
BMC infectious diseases has published our paper on HIV-1C epidemic in Ethiopia, using data collected starting from our EDCTP project
Moscow, 11-13 October 2016
EuResist participates in the II RCLM where EuResist partner Prof. Bobkova is organizer of the Virology section.
Seattle, 2-7 October 2016
A novel engine predicting time to HIV rebound as been presented at ACM conference on Bioinformatics and Computational Biology, oral presentation.
Siena, 6-7 October 2016
EuResist participates in the organization of the second AMS event in Siena: hands-on training on querying clinical-genetic DBs.
Stockholm, 28-30 September 2016
EuResist participates in the 3rd regional annual event, co-organised by EuResist partner Prof. Sonnerborg.
Cologne, 29-30 April 2016
For registration and accommodation:
Erbil, 24-29 February 2016
During the second mission of the KRG SHMS Project, the pilot monitoring system has been installed in 10 test centres in Erbil, Dohuk and Suleymania.
The EuResist Engine has been retrained to predict response after 48 weeks from treatmennt start, on a database of more than 66.000 patients. Performance is 0.73 - 0.76 AUC